Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
about
Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolatesCurrent and emerging azole antifungal agentsIn vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungiEvaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosisIn vitro and in vivo antifungal activities of D0870, a new triazole agentT-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluationsThe therapeutic monitoring of antimicrobial agents.Tinea capitis: an overview with emphasis on management.Organism-dependent fungicidal activities of azoles.Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycosesDose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosisSafety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.Tinea capitis.In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis.Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisReview of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis.Antifungal proteinsA controlled study to determine the efficacy of Loxostylis alata (Anacardiaceae) in the treatment of aspergillus in a chicken (Gallus domesticus) model in comparison to ketoconazoleHuman pharmacogenomic variations and their implications for antifungal efficacy.Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.Current perspectives on ophthalmic mycosesComparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient.High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyDefining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.The hypermetabolic response to burn injury and interventions to modify this responseProphylactic antifungal agents used after lung transplantation.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Metal-organic frameworks as solid catalysts for the synthesis of nitrogen-containing heterocycles.Formulation and Evaluation of Long Circulating Liposomal Amphotericin B: A Scinti-kinetic Study using Tc in BALB/C Mice.Influence of human serum on antifungal pharmacodynamics with Candida albicans.Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolatesVariation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.Physicochemical cell damage in relation to lethal amphotericin B action.Amphotericin B and its lipid formulations.Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae.Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.
P2860
Q24550639-A134C51F-7829-4483-8A7A-FF921490FA9AQ24550733-0BA80917-E69F-431B-9C11-D7747E4A1FA2Q28367448-3D5D2607-C62F-4063-8388-8FB503CFCBD3Q28367890-C08138E1-A08A-4804-8892-D6401FA271AAQ28378447-E120C7B8-EF46-49A9-88F1-8EB36AD8448BQ28379379-E26F92C0-B7FD-49C6-A38E-37ADC2A859CEQ33540451-52BABAC9-C323-4343-90FD-A8748DFBF6BCQ33670881-21B241E0-8D5A-44D5-974B-B3193A441DDFQ33702101-3A1CE1E4-325E-4378-A081-D30EFDB80BA1Q33749120-6466A324-4551-4004-B8D6-466FD7E1718BQ33751032-C07ECFE7-105B-40FB-9ED1-026E62A837BEQ33824631-3A74E3D4-C4A5-4CAF-8336-60EDD6C65D1CQ33916883-763B72D3-DDFF-4C86-87E4-95E9C7E10FD0Q33965202-6C4CF20A-F751-4B69-9256-6B513C80EA4AQ33980413-AB437F82-ABE3-4171-B451-8EEAC74DAA41Q34098069-B79B9B0F-E7DA-4B32-A9C7-237E359ECDF7Q34293126-A75FBE2E-025A-4405-AAFE-BAF48A643F42Q34462896-4041E587-A17A-4733-8BF6-D684FD60296FQ35070838-E654E2E9-B928-4B24-81C1-8E42DF8E87DDQ35114249-54B0926B-CDA0-474B-AA25-09B74B0CDF49Q35118084-A815D2FF-11AC-4758-9F28-9EC503E012B6Q35558829-8158538C-8C5A-4D69-A109-160CF577A178Q36489697-7C665C7B-E6D3-4F94-BB50-9588E7CE2620Q36534003-EB8A8B1D-4601-4294-81CA-902087689734Q37016279-01D3CC1D-F4F1-4DD0-A8D3-9CCCEA28D37CQ37157893-341E0640-5B01-42D5-8656-8056010403C8Q37181299-4088841C-2518-43AB-9136-7A80E68C2A51Q37697380-58645790-021D-4CDF-862D-CC7AE7303950Q38193337-4FBDF3D7-8ECC-48EF-A08F-918C5EC55F0BQ38194920-5E1E3A9F-C6EF-4E55-802C-6E6B1284C1BAQ39384410-6C63EA7A-C8B0-41FC-B8D3-362D49E94653Q39477738-FAEC91E6-627B-4B49-BAF6-DC60F83E277DQ39558155-5A0E8F8A-DBB3-4782-8B19-0C06A9E5E834Q39650951-FC30420A-6ED1-4CF0-95FC-CD3DBF01ABE4Q39782173-B0E27060-1676-40C8-B130-6DB082B06432Q40285078-A2C3F0E6-FB12-475D-9EC7-BD40C57EE627Q40626316-C1B22CBC-6A88-4BE3-A184-19C6E8990B1CQ44489725-7CC1BFBF-C226-450E-A88C-1E4235CA218BQ44564506-43321B0F-9974-4338-A1EB-87F53611A51BQ45754321-5C31E4CF-C646-4778-BA5A-4B7D54CC3A38
P2860
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Systemically administered anti ...... and therapeutic applications.
@ast
Systemically administered anti ...... and therapeutic applications.
@en
type
label
Systemically administered anti ...... and therapeutic applications.
@ast
Systemically administered anti ...... and therapeutic applications.
@en
prefLabel
Systemically administered anti ...... and therapeutic applications.
@ast
Systemically administered anti ...... and therapeutic applications.
@en
P1433
P1476
Systemically administered anti ...... and therapeutic applications.
@en
P2093
P356
10.2165/00003495-199244010-00002
P577
1992-07-01T00:00:00Z
P6179
1042156997